KB-1225

Tusamitamab

52680

Home » Tusamitamab

Background of Tusamitamab

Carcinoembryonic antigen (CEA)-related cell adhesion molecule 5 (CEACAM5, also known as CD66e), a cell surface glycoprotein, is weakly expressed in normal epithelial tissues including colon, esophagus, head and neck, stomach, and cervix tissue but is highly expressed in several tumor types including gastrointestinal, lung, and breast. Tusamitamab ravtansine (SAR408701) is an antibody-drug conjugate composed of a humanized monoclonal antibody that binds carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5) and a cytotoxic maytansinoid that selectively targets CEACAM5-expressing tumor cells.

Specifications

Catalog Number	KB-1225
Antibody Name	Tusamitamab
Isotype	Human IgG1,kappa
FC Muations	Wild Type
Target	CEACAM5
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

S. Decary, P.-F. Berne, C. Nicolazzi, et al. Preclinical activity of SAR408701: a novel anti-CEACAM5-maytansinoid antibody-drug conjugate for the treatment of CEACAM5-positive epithelial tumors. Clin Cancer Res, 26 (2020), pp. 6589-6599.
S. Hammarstrom. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol, 9 (1999), pp. 67-81.